← All stocks

Cue Biopharma, Inc.

CUE Net selling
CIK 0001645460 #3995 in the set updated 17 Sep 2026
Bought (12 mo)
$99.75K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$2.04M
$0.00 on a plan · $1.52M straight out of an exercise
Sold at will
$522.57K
3 of 11 sales
Net
−$1.94M
−$422.83K against sales at will

By person

10 insiders · 16 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Lin Shao-Lee
Chief Executive Officer
$1.61M (5) scheduled
−$1.61M
705,995
$20.81M
Ray Sumita
Chief Legal Compliance Officer
$265.63K (3) scheduled
−$265.63K
118,545
$3.49M
+117.2%
Meluzio Michael Vincent
VP, Prin. Accounting Officer
$169.32K (3) scheduled
−$169.32K
48,961
$1.44M
Sarraf Pasha
Director
$99.75K (5)
+$99.75K
32,595
$960.90K
PASSERI DANIEL R
CHIEF EXECUTIVE OFFICER
164,578
$4.85M
+22.3%
Borie Dominique Christian
Chief Medical Officer
31,500
$928.62K
Ahlers James M
Chief Financial Officer
25,500
$751.74K
Garzone Pamela
Director
21,800
$642.66K
Camardo Daniel A.
Director
21,800
$642.66K
Meehan Viola Mong
Director
21,800
$642.66K

No percentages here. This company's share count has moved by a factor of 13.4 over the window, from 7,264,414 to 97,660,791 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 30
Amendments (4/A) skipped 3
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 8
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 1,035,827
History held since 27 Dec 2017